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Summary 
 
OBJECTIVE  To evaluate the psychometric properties of two health status measures 
for adults with growth hormone deficiency (GHD): Nottingham Health Profile (NHP) 
and Short-Form Health Survey (SF-36).  
DESIGN  (1) A cross-sectional survey of adults with treated or untreated GHD, to 
assess reliability and validity of the questionnaires. (2) A randomised, placebo-
controlled study of 3 months’ GH withdrawal from GH-treated adults, to assess the 
questionnaires’ sensitivity to change.  
PATIENTS  (1) Cross-sectional survey of 157 patients with severe GHD (peak GH < 
10mU/L on provocative testing), mean age 48.9 (range 23-70), who had either 
received GH-replacement therapy for at least 6 months immediately prior to the 
study, or had not received GH treatment in the previous 6 months. (2) GH treatment 
was withdrawn from 12 of 21 GH-treated adults, all with severe GHD (peak GH < 7.7 
mU/L on provocative testing), mean age 44.9 (range 25–68). 
MEASUREMENTS  The NHP and SF-36 were used once in the cross-sectional 
survey, but twice in the GH-withdrawal study, at baseline and end-point (after 3 
months). 
RESULTS  (1) Cross-sectional survey. Both questionnaires had high internal 
consistency reliability with subscale Cronbach’s alphas of > 0.73 (NHP) and > 0.78 
(SF-36). Calculation of a NHP Total score, occasionally reported in the literature, was 
shown to be inadvisable. Overall, patients with GHD were found to have significantly 
worse perceived functioning than the UK general population in SF-36 subscales of 
General Health, Pain, Social Functioning, Role-Emotional, Role-Physical, and 
Vitality. Whilst neither questionnaire found significant differences between GH-
treated and non-GH-treated patients, there were correlations with duration of GH 
treatment (p < 0.01) for GH-treated patients, in SF-36 Mental Health [r = 0.29, N = 
87] and SF-36 Vitality [r = 0.33, N = 88], indicating improvement with increasing 
treatment duration. The SF-36 was also more sensitive than the NHP to sex 
differences: men had significantly better health status compared with women (p < 
0.05) in all SF-36 subscales but Mental Health, but only in one NHP subscale 
(Physical Mobility). (2) GH-withdrawal study. Significant between-group differences in 
change were found in SF-36 General Health [t(17) = 2.76, p = 0.013, 2-tailed] and 
SF-36 Mental Health [t(17) = 2.41, p = 0.027, 2-tailed]: patients withdrawn from GH 
reported reduced general health and mental health at end-point. The NHP found no 
significant change.  
CONCLUSIONS  The SF-36 is a better measure than the NHP of health status of 
people with GHD, owing to its greater discriminatory power with ability to detect 
lesser degrees of disability. It also has superior sensitivity to some sub-group 
differences and superior sensitivity to change than the NHP. The SF-36 is highly 
acceptable to respondents, and has very good internal consistency reliability. The 
SF-36 is recommended to measure the health status of adults with GHD.  
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Introduction 
 
The physical symptoms of adult GHD include abnormal body composition with 
reduced lean body mass and increased central adiposity; reduced muscle strength 
and exercise performance (Carroll et al. 1998). However, psychological symptoms 
may be as important as physiological (Powrie et al. 1995) and it has been 
recommended that psychological variables should be considered when assessing 
patients for treatment (Bengtsson et al. 2000). Psychological symptoms reported by 
adults with untreated GHD include low energy, tiredness, sleepiness, poor 
concentration, poor memory, irritability (Hunt et al. 1993), anxiety, depression and 
mood swings (Wallymahmed et al. 1996).   
 
Health status has been one of the key psychological outcomes in adult GHD 
research and the NHP (Hunt et al. 1985) the most frequently used health status 
questionnaire with this patient group. The NHP has 6 subscales to measure 
Emotional Reactions, Energy, Pain, Physical Mobility, Sleep and Social Isolation. 
After 6 months’ GH treatment in placebo-controlled studies improvements have been 
found in Energy (McGauley et al. 1990; Mardh et al. 1994; Carroll et al. 1997; 
Wallymahmed et al. 1997); Emotional Reactions (Carroll et al. 1997); Physical 
Mobility and Social Isolation (Attanasio et al. 1997; Carroll et al. 1997). One study 
only obtained significant improvement in Emotional Reactions and Energy when 
patients with floor baseline scores1 were excluded from analysis (Burman et al. 
1995).  Others only found improvements in some NHP variables in the open label 
stages of the trial after 12+ months’ GH treatment (Cuneo et al. 1998; Mardh et al. 
1994), or after 20-50 months (Wiren et al. 1998). Some studies found no significant 
effects using the NHP (Whitehead et al. 1992; Baum et al. 1998). Thus energy has 
generally been found to improve when patients with GHD are given GH replacement 
therapy, but results for other aspects of health status have not always been 
consistent. The SF-36, a more recent measure of health status (Ware & Sherbourne 
1992), has 8 subscales to measure Bodily Pain, General Health, Mental Health, 
Physical Functioning, Role-Emotional, Role-Physical, Social Functioning and Vitality.  
It has been used less frequently than the NHP in research into adult GHD, generally 
in comparison studies.  
 
Both the NHP and SF-36 measure how people feel about their health, but they have 
often been inappropriately referred to as measures of quality of life (QoL) in the 
research literature, where the terms “health status” and “quality of life” are frequently 
misused as if interchangeable (Bradley 2001; Smith et al. 1999). Even if people feel 
that their health is poor, they may or may not also feel that their QoL is impaired, and 
vice versa. Treatments that improve health may conversely damage QoL, and may 
lead to poor adherence to therapy.  “When a health-status measure is used to assess 
quality of life, the conclusions can be misleading” (Bradley 2001). 
 
GH replacement therapy in adult GHD is not the norm in the UK, as there is 
controversy about whether the benefits outweigh the high financial costs and a 
treatment regimen requiring daily injections. Measures of psychological outcomes are 
required in addition to clinical outcomes to assess the effects of GH treatment. The 
frequently used NHP does not appear to have been previously validated 
psychometrically for use in adult GHD, and the opportunity was taken in the two 
studies described below to validate not only the NHP, but to compare its properties 
                                                
1 Good health status. 
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with those of the SF-36, which has been shown to be more sensitive than the NHP in 
the general population (Brazier et al. 1992). The first study was a cross-sectional 
survey of 157 adults with severe GHD, both GH-treated and non-GH-treated, to 
investigate reliability, factor structure and construct validity of the questionnaires.  
Sensitivity to change was investigated in a randomised placebo-controlled study of 3 
months’ withdrawal of GH treatment from 12 of 21 GH-treated adults, where 9 
continued with GH. The Guy’s and St Thomas’ Hospital Trust Ethics Committee gave 
approval for both studies. 
 
The questionnaires 
NHP 
The NHP has 38 dichotomous negatively-worded items. ‘No’ responses (indicating 
good functioning) score zero, ‘yes’ responses can be weighted as described in the 
manual (Hunt & McKenna 1989). Subscale scores range from 0 to 100, (lower scores 
indicating better health status).  
SF-36 
The 36-item SF-36 has 8 subscales with Likert scales of 2 to 6 response options and 
an additional item on perceived change in health over the previous year. SF-36 
subscale scores range from 0 to100, (higher scores indicating better functioning). 
The UK version was used in the present studies. It was found to have high reliability 
with a UK general population (Brazier et al. 1992), and was able to detect low levels 
of ill health in people who had scored 0 (indicating good health) on the NHP. 
 
Both questionnaires have been used in the endocrine field.  For example in hormone 
replacement therapy (Kenny et al. 2002; Ryan & Rosner 2001), diabetes (Anderson 
et al. 1997; Benbow et al. 1998), thyroid disease (Burney et al. 1999), and Addison’s 
disease (Lovas et al. 2002).   
Other questionnaires 
Other questionnaires were also completed in these studies including the General 
Well-being Index2 (Hunt & McKenna 1992), the Well-being Questionnaire (Bradley 
1994), and a new hormone deficiency-specific individualised QoL questionnaire 
(HDQoL) (Bradley 1999), the results for which have been reported previously 
(McMillan & Bradley 2000), (McMillan et al. 2001), (McMillan 2001) (PhD thesis). 
 
I. The cross-sectional survey of GH-treated and non-GH-treated 
adults with GHD 
Recruitment procedures 
 
All participating patients had been diagnosed with GHD and received GH-
replacement therapy for at least 6 months immediately prior to the study or had not 
received GH treatment in the previous 6 months; were aged between 18-70 years; 
had received appropriate adrenal, thyroid and gonadal hormone replacement 
therapy, as required by their hormonal condition, for at least 12 months prior to the 
                                                
2 The British version of the Psychological General Well-being Index (Dupuy 1984). 
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study. Patients might have adult onset of GHD (AOGHD) or childhood onset 
(COGHD). Exclusion criteria were diabetes mellitus, active malignancy or pregnancy. 
The patients were to be severely GH deficient as determined by an Insulin Tolerance 
Test (ITT) or Pituitary Function Test in which insulin reduced blood glucose to ≤ 2.5 
mmol/ L with peak GH concentration ≤ 10 mU/ L. However, there were no ITT results 
available for 21 patients because an ITT was too dangerous, an ITT had never been 
performed or because the laboratory test results were missing from the patient notes.  
In 18 of these 21 cases the assumption was made that because the patients were 
already receiving GH treatment, were about to be given GH treatment, or had 
received it in the past as adults, then the severity of the deficiency had been 
established, and that they could be included in this study.  In 3 cases in the non-GH-
treated group, clinicians were consulted about the patient's suitability for inclusion. 
Some patients were approached in a mailshot enclosing the questionnaires, others at 
weekly clinics. 
 
Statistical analyses  
 
Normality issues: Normality of distributions was investigated through standardised z 
(skew) values (Tabachnik & Fidell 1983). Item data were not transformed to 
normality, thereby sacrificing some of the accuracy of factor analyses for the 
convenience of having interpretability of original units.  The assumption was made 
that if reliability were high, the factor analysis robust, and the number of respondents 
sufficiently high, then a degree of non-normality was acceptable. In sub-group 
analyses, Mann-Whitney tests were performed on skewed variables, and t-tests on 
normal data. 
Internal consistency reliability: Cronbach’s alpha coefficients (Cronbach 1951) were 
determined, with acceptable alphas ranging from 0.7 (Todd & Bradley 1994) to 0.95. 
Acceptable item-total correlations were > 0.2 (Kline 1993). 
Factor structure was explored with Principal Components Analysis. Forced one-factor 
solutions were obtained for individual subscales to confirm the validity of calculating 
subscale totals. Salient loadings were taken as ≥ 0.4, higher than the recommended 
minimum 0.3 (Kline 1994), erring on the side of caution in an effort to reduce the risk 
of spurious loadings that owed their origin to non-normality of item distributions.   
Construct validity was sought in some expected sub-group differences (GH-treated 
patients having generally better health status than non-GH treated patients, and men 
better than women). Health status was expected to improve with increasing duration 
of treatment and correlations were undertaken (for GH-treated patients).  
‘Familywise’ error in multiple tests: The Holm’s sequential Bonferroni procedure for 
multiple tests, cited (Green et al. 1997), was adopted.  A minimum significance value 
of 0.006 was required if 8 similar statistical tests were performed on the 8 subscales 
of the SF-36 and 0.008 for the 6-subscale NHP. 
 
Analysis was conducted using SPSS for Windows (Release 7.5). 
 
Results 
The patient sample 
Of 219 questionnaires distributed, 163 were returned (74.4% response rate), but 6 
patients did not meet all inclusion criteria (e.g. were found to have diabetes mellitus), 
leaving 157 data sets for analysis.  Fifty-six people either declined to participate or 
did not respond (23.5% GH-treated and 29.8% non-GH-treated patients).  
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Ninety-one GH-treated and 66 non-GH-treated patients participated. T-tests showed 
no significant between-treatment-group differences in Body Mass Index (BMI) or 
height (Table 1); Chi-Square tests showed no differences in numbers of men but the 
difference in numbers of GH-treated women (51) and non-GH-treated women (33) 
was significant. The mean age of GH-treated patients (47.1 years) was significantly 
younger than non-GH-treated patients (51.3 years). There were significantly more 
people with COGHD in the GH-treated group (21) than the non-GH-treated group (9). 
 
(Table 1 here) 
 
Questionnaire completion rates were high: 98.5% (NHP) and 99.1% (SF-36) 
indicating high acceptability to respondents.  Non-normality, (distributions skewed 
towards good health status), was found in a much greater proportion of NHP items 
(36/38) than SF-36 items (20/36). Indeed 31/38 dichotomous NHP items had ≥ 75% 
‘No’ responses, indicating good health, and 23.7% of respondents scored ‘No’ on all 
38 NHP items. The highest levels of dysfunction in the whole patient sample, found 
by the NHP, were for Energy (mean 34.28 ± 39.48, N = 153) and Sleep (21.34 ± 
30.65, N = 153). The SF-36 found highest dysfunction in Vitality (mean 49.59 ± 23.8) 
and General Health (56.0 ± 25.04).  However, when compared with the results for the 
UK general population (Garratt et al. 1993), the patient sample as a whole was found 
to have significantly worse perceived functioning in SF-36 subscales of General 
Health, Pain, Social Functioning, Roles Emotional and Physical, and Vitality (Table 
2).  These results were similar to those found by other researchers when comparing 
healthy controls and patients with GHD e.g. in the Belgian population (Hakkaart-van 
Roijen et al. 1998).  
 
 
(Table 2 here) 
Reliability Analyses 
NHP: All subscale alpha coefficients were acceptable (range: 0.74 to 0.89) and 
corrected item-total correlations within subscales satisfactory (range: 0.22 to 0.62). 
Reliability analysis of the whole NHP scale found a high Cronbach’s alpha (0.92) but 
also indicated the unacceptability of the NHP Total score occasionally reported in the 
literature, as corrected item-total correlations for two items failed to reach the 0.2 
criterion.  
SF-36: All subscale alphas were high for short scales of from 2 to 10 items (range: 
0.78 to 0.94) and corrected item-total correlations within subscales were satisfactory 
(range: 0.43 to 0.89).  
Factor analysis  
NHP: Forced 1-factor analyses of the individual subscales found satisfactory loadings 
≥ 0.4 for all except one Physical Mobility item which loaded at 0.321. A forced 1-
factor analysis of the whole scale found 10/38 items loading at < 0.4, again indicating 
the invalidity of calculating an overall NHP Total Score.  
SF-36: Forced 1-factor analyses of subscales found all loadings satisfactory (≥ 0.57).  
 
With the exception of NHP Physical Mobility, analyses supported the calculation of 
NHP and SF-36 subscale scores for adults with GHD. 
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Subgroup differences 
 
GH-treatment group differences   
NHP: There were no significant differences on Mann-Whitney tests between the 
treatment groups (p values in range 0.16 to 0.99), though trends were in the 
expected direction of those receiving GH treatment having better health status than 
non-GH-treated patients on all subscales except Social Isolation.  
SF-36: T-tests were performed on all SF-36 subscales but the skewed Physical and 
Social Functioning subscales, for which Mann-Whitney tests were conducted. There 
were no significant between-treatment-group differences: p values in range 0.09 
(Mental Health) to 0.83 (Role-Emotional).  GH-treated patients had slightly better 
functioning than non-GH-treated patients in all subscales but Bodily Pain, Mental 
Health and Physical Functioning. A further analysis, excluding the 21 patients who 
did not meet the initial inclusion criteria (no ITT test result available), did not find any 
significant between-treatment-group differences. 
  
 
 
Correlations with duration of GH treatment in GH-treated patients  
NHP: No correlations were significant once Bonferroni corrections had been applied.  
SF-36: Mental Health correlated significantly with duration of GH treatment  [r = 0.29, 
p = 0.007, N = 87] as did Vitality [r = 0.33, p = 0.002, N = 88], indicating, as expected, 
improved mental health and vitality with increased duration of treatment.   
 
Age of onset of GHD 
Neither questionnaire found significant differences in health status between those 
with AO or COGHD once Bonferroni corrections had been applied (full results not 
supplied).  
 
Sex differences  
Men had significantly better NHP Physical Mobility and significantly better health 
status in all SF-36 subscales but Mental Health compared with women (Table 3).  
These are similar to results for the UK general population (Brazier et al. 1992).  
 
(Table 3 here) 
 
II. The randomised placebo-controlled trial of withdrawal of GH 
treatment from GH-treated adults. 
Study Design 
Patients were allocated to placebo or continued treatment with GH in a randomised, 
double-blind, placebo-controlled, parallel-groups study, in which patients self-
administered either GH (0.125 to 0.25 IU/ kg body weight/ week) or placebo for a 
period of 3 months. Lilly Industries Ltd supplied the vials of GH (Humatrope) which 
were indistinguishable from placebo. IGF-I was measured by double-antibody 
radioimmunoassay after acid/ ethanol extraction, using a commercially available 
reagent pack (Amersham, Arlington Hts., III., within-assay c.v. < 5%). Questionnaires 
were given at baseline and end-point, 3 months later. All patients were attending the 
Endocrine Clinic of St Thomas’ Hospital, London.  
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Recruitment procedures  
Inclusion and exclusion criteria were similar to those in the cross-sectional study 
above except that all participating patients had received GH-replacement therapy for 
at least six months immediately prior to the study; were aged between 22-70 years; 
were taking adequate contraception, if women of childbearing age and potential. All 
patients had endogenous GH levels of ≤ 7.7 mU/ L at blood glucose ≤ 2.0 mmol/ L on 
provocative testing.  Additional exclusion criteria were: clinically significant 
pulmonary, cardio-thoracic, renal or neuromuscular disease; clinically apparent 
chromosomal or genetic malformation syndromes; a history of alcohol or drug abuse; 
were unlikely to comply with the protocol; were taking oral and parenteral steroids, 
other than in replacement doses, which were likely to suppress the action of GH. 
Prospective participants were approached personally by clinicians. 
Additional measures  
Interviews were also conducted, results for which have been reported (McMillan 
2001). The number of serious negative life events and difficulties occurring in the 12 
months prior to this study was assessed in the interviews using a short checklist [Life 
events and difficulties screening checklist]3 modified from a screening checklist for 
stressful life events and chronic difficulties (Costello & Devins 1998). 
 
Hypotheses 
When adults with GHD are given GH treatment, improvements in health status have 
been reported. There was general clinical expectation of deterioration in physiological 
/metabolic factors within the 3-month study period and that this might be 
accompanied by reduced health status (Sönksen et al. 1991).  It was therefore 
hypothesised that after 3 months’ withdrawal of GH the Placebo group would exhibit, 
relative to baseline, decreased Energy, Emotional Functioning, Physical Mobility, 
Sleep and increased Social Isolation (higher scores on NHP); and decreased 
General Health, Mental Health, Physical Functioning, Social Functioning, and Vitality 
(reduced scores on SF-36) but GH-treated patients would show little change. 
  
Statistical analyses 
T-tests or Mann-Whitney tests were conducted on the differences between the 
treatment-group change scores over the withdrawal period. Bonferroni corrections 
were not applied to reduce the chance of Type II errors in a study with small sample 
size, and as it was unlikely that a significant result that had been predicted would be 
obtained by chance. The required significance level was set at < 0.05. 
Results 
The patient sample 
Only 66 of the 144 adults with GHD being treated with GH at St Thomas’ Hospital 
fulfilled the stringent inclusion criteria and were approached.  However, 62% declined 
to participate, the majority because they were satisfied with their current treatment – 
not wishing to risk withdrawal, with expected return of undesirable symptoms of 
GHD. Twenty-two patients were finally recruited into the study, but one patient 
withdrew from psychological aspects of the study just prior to baseline, and another 
(Placebo group), withdrew suddenly and prematurely from the study, about 2 weeks 
                                                
3 Unpublished, available from author, Dr Bernice Andrews, at Psychology Department, Royal Holloway, 
University of London, Egham, Surrey, TW20 0EX. 
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prior to end-point, owing to adverse symptoms. There was no significant difference in 
the number of men (23) and women (18) who declined to participate in the study, or 
in the age of people who refused and people who participated. The study sample 
was therefore representative of the patient pool in terms of age and sex. 
 
Table 4 shows patient characteristics. At baseline, the Placebo group had 
significantly higher BMI (31.3 kg/ m2) compared with the GH-treatment group (24.7).  
  
(Table 4 here) 
Biochemical changes  
Three months after baseline the serum total IGF-I of placebo-treated patients fell 
from normal, age-related levels (mean 26.6 ± 3.8 nmol/ L) to levels indicative of 
severe GHD (11.6  ± 1.9 nmol/ L) (p < 0.001). Only a small, non-significant decrease 
was noted in GH-treated patients. 
 
One patient in the GH-treatment group reported several adverse symptoms over the 
course of the withdrawal period. A large drop (-20.2 nmol/L or 39.3%) in his IGF-I 
levels were noted over the study, well outside the mean change of -1.74 ± 10.68 for 
the GH-treatment group and more than the mean change of -15.02 ± 12.38 in IGF-I 
levels for the Placebo group. However, his IGF-I level at end-point was in the normal 
range. After the study codes had been broken, the patient was asked if there were 
any reasons for this and he claimed that the injection pen may have malfunctioned.  
It is also possible that he did not fully adhere to the injection regimen, as he had a 
history of non-adherence. Analyses were therefore undertaken excluding the data of 
this anomalous case. 
Questionnaire data 
NHP: no significant between-group differences in change scores were found in 
Mann-Whitney tests. SF-36: As expected, a significant between-group difference in 
change was found in SF-36 General Health [t(17) = 2.76, p = 0.013, 2-tailed] with 
scores of placebo-treated patients dropping from 63.5 ± 19.6 at baseline to 57.0 ± 
23.2, but scores of GH-treated patients increasing from 62.8 ± 23.9 to 66.1 ± 25.2, 
and for SF-36 Mental Health [t(17) = 2.41, p = 0.027, 2-tailed] with scores of placebo-
treated patients dropping from 75.0 ± 15.9 at baseline to 69.5 ± 21.0, but scores of 
GH-treated patients increasing from 77.5 ± 20.1 to 84.5 ± 7.2. Patients withdrawn 
from GH reported reduced general health and mental health at end-point. (Table 5).   
 
Analysis of the single health transition item showed that, by end-point, 4 of the 12 
placebo-treated patients (33.3%) considered their health worse than one year before, 
but only one patient in the GH-treated group (the outlier whose IGF-I levels dropped 
considerably). 
 
(Table 5 here) 
Discussion  
The NHP has been one of the most frequently used questionnaires in research into 
adult GHD, yet it is known to have certain disadvantages. It is designed for more 
severe illness and therefore has highly skewed distributions in relatively healthy 
populations, with reduced sensitivity to between-group differences, reduced 
sensitivity to change (Bowling 1991) and inability to detect low levels of morbidity. 
Such criticisms were confirmed in the present studies. For all individual NHP items 
the majority of respondents in the cross-sectional survey answered ‘No’, that they 
perceived no health problem in that area, indeed almost a quarter of respondents 
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reported no health problem in any of the 38 items. The wider range of SF-36 
response options means that more information is available about different degrees of 
impairment, thus the SF-36 had greater discriminatory power. Responses to 
individual items of the SF-36 showed that most respondents in the cross-sectional 
survey were not limited at all in moderate activities and only felt limited in vigorous 
activities such as climbing several flights of stairs. However, patients had significantly 
worse health status for most SF-36 subscales than the UK general population.   
 
Both NHP and SF-36 have good acceptability to adults with GHD (as indicated by 
high completion rates), and good internal consistency reliability. However, reliability 
and factor analyses of the whole 38-item NHP scale confirmed the inadvisability of 
calculating a NHP Total score, as occasionally reported in the literature.  
 
In the cross-sectional study the SF-36 showed more sensitivity to expected sex 
differences than the NHP. Women had significantly worse health status than men on 
all SF-36 subscales but Mental Health, but on only one NHP subscale, (Physical 
Mobility). In the general population, women’s health status is worse than men’s, 
(Brazier et al. 1992; Hunt & McKenna 1989), and in adult GHD women have also 
tended to exhibit worse health status (NHP) than men. No significant differences in 
health status were found between patients with CO and AOGHD although these are 
different clinical entities (Attanasio et al. 1997): CO patients are more 
underdeveloped physically and AO patients have greater lipid abnormalities. There 
have been few studies comparing health status in the two groups. Whilst one study 
found no difference in health-related QoL (Abs et al. 1999) another study found 
significantly reduced physical mobility and energy in AO than COGHD (Attanasio et 
al. 1997).  
 
Whilst the SF-36 Mental Health and Vitality subscales showed correlations indicative 
of improving health status for GH-treated patients with longer periods of GH 
treatment, neither questionnaire found significant GH treatment-group differences. It 
could be that neither questionnaire was sensitive to treatment group differences, or 
that there were no real differences in perceived health status between the 2 groups. 
It may be that people prescribed GH treatment present with more serious symptoms 
of mental and physical ill-health but GH treatment improves their health status to a 
level little different from people with GHD who are untreated perhaps because they 
are managing quite well without it. The results appear to indicate that an appropriate 
subgroup of patients were prescribed GH treatment - perhaps the result of a 
combination of clinical acumen and patient pressure from those adversely affected by 
GHD. In the study as a whole, however, significant findings were limited to a few 
selected comparisons (e.g. sex differences and differences from the healthy general 
population). Insufficient data were available to conduct further analyses of between-
group differences.  
 
Recruitment difficulties for the GH-withdrawal study indicated that the majority of 
patients did not want to risk withdrawal from GH-treatment, and the anticipated 
negative effect that it would have on their lives. The small pool of patients suitable for 
inclusion in the GH-withdrawal study, combined with a high refusal rate, resulted in a 
small sample of 21 patients, and low power of analysis. One placebo-treated patient 
withdrew from the study just prior to end-point owing to adverse symptoms. The 
possible non-adherence to the study protocol of one GH-treated patient further 
reduced the data available for analysis. Whilst it might have been more logical and 
less problematic to investigate the questionnaires’ sensitivity to change with GH 
replacement, for which there would be no recruitment problems, there was no 
opportunity for such a study at the time. 
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In the GH-withdrawal study, where health status of placebo-treated patients was 
expected to worsen, the NHP found no significant between-treatment-group 
differences.  The SF-36, on the other hand, had two significant findings in the 
expected direction (of worsening health in the Placebo group) in the General Health 
and Mental Health subscales. In a study such as the GH-withdrawal study, where 
power was low, the NHP was not sufficiently sensitive to change. It is possible that 
some of the negative findings for the benefits of GH treatment in the literature, might 
have been the result of the lack of sensitivity of the questionnaire chosen to measure 
change, the NHP.  
 
The relationship between hormonal abnormalities and psychological consequences 
is complex (Fava et al. 1993).  These studies did not cover the effects of patients’ 
other hormone deficiencies or endocrine disease (if any). Patients with diabetes were 
excluded from the studies, and only those patients who were being treated with 
appropriate adrenal, thyroid and gonadal hormone replacement therapy were 
included. However, there is some evidence that some patients still exhibit 
psychological symptoms (particularly depression or anxiety) even if their hormone 
levels have been normalised with therapy (Lovas et al. 2002; O'Malley et al. 2000; 
Sonino & Fava 2001). Full details of other hormone deficiencies were not recorded in 
the cross-sectional study, although are available for the longitudinal study.  It is not 
possible to say whether any psychological distress was due to another endocrine 
condition, but this should be borne in mind when interpreting results.    
 
Conclusion 
In conclusion, the present studies have shown that the SF-36 is a better measure 
than the NHP of health status of people with GHD, owing to its greater discriminatory 
power with ability to detect lesser degrees of disability. It also has superior sensitivity 
to some sub-group differences and superior sensitivity to change than the NHP. The 
SF-36 is highly acceptable to respondents, and has very good internal consistency 
reliability. The SF-36 is recommended to measure the health status of adults with 
GHD.  
 
Questionnaire availability 
The NHP is available from Dr. Stephen McKenna, Galen Research, Enterprise 
House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, UK.  
The SF-36 is administered by the Medical Outcomes Trust, 8 Park Plaza #503, 
Boston, MA 02116, USA. Licence agreement details are obtainable from 
www.qualitymetric.com. 
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Tables 
 
Table 1: Characteristics of patients in the cross-sectional survey 
 GH treatment  
(N = 91) 
No GH treatment  
(N = 66) 
P 
Women  51 33 = 0.05 
Men  40 33  
COGHD 21 9 < 0.05 
AOGHD  70 57  
Isolated GHD 5 1  
Multiple hormone 
deficiency  
86 65  
Mean age (years)  
[range] 
47.1 ± 12.6  
[23.7 – 70.9] 
51.3 ± 12.4 
[23.8 – 70.9] 
< 0.05 
Mean duration GHD (years) 
(AOGHD)  
13.0 ±  6.8  13.2 ± 7.8  
BMI (kg/ m2) 27.2 ±  5.5 28.0 ±  5.3  
Height (cms)  167.5 ± 10.5 168.7 ± 10.6  
 
  
 
Table 2: SF-36 subscale means and comparison with UK general population 
Subscale N Mean **UK 
mean 
P 
Bodily Pain 156 68.99 ± 7.48 76.9 < 0.001 
General Health 152 56.0  ± 25.04 68.7 < 0.001 
Mental Health 156 70.79 ± 19.56 73.7  
Physical Functioning 157 72.06 ± 24.22 79.2 < 0.001 
Role-Emotional 156 64.96 ± 39.49 75.0 < 0.01 
Role-Physical 155 58.92  ± 40.23 76.5 < 0.001 
Social functioning 156 73.56  ± 26.86 78.6  
Vitality 157 49.59 ± 23.8 61.2 < 0.001 
Subscale range 0-100, with higher score indicating better health status/ functioning. 
**Means for a healthy UK general population, from Garratt et al. (1993). 
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Table 3: Means for men and women in the cross-sectional survey 
 Men Women P  
NHP     
Emotional Reactions 11.92 ± 18.49 19.79 ± 27.37  
Energy 26.39 ± 35.9 41.28 ± 41.37  
Pain 7.70 ± 19.6 13.91 ± 24.97  
Physical Mobility 7.44 ± 15.96 12.59 ± 18.01 < 0.01 
Sleep 17.70 ± 29.06 24.65 ± 31.85  
Social Isolation 13.58 ± 23.78 16.98 ± 26.2  
SF-36     
Bodily Pain 78.06 ± 23.99 61.23 ± 28.03 < 0.001 
General Health 62.28 ± 22.87 50.35 ± 25.70 < 0.01 
Mental Health 73.81 ± 18.32 68.14 ± 20.33  
Physical Functioning 80.43 ± 19.75 64.79 ± 25.47 < 0.001 
Role-Emotional 73.97 ± 35.24 57.03 ± 41.49 < 0.05 
Role-Physical 71.00 ± 37.84 48.17 ± 39.44 < 0.001 
Social Functioning 78.60 ± 25.89 69.13 ± 27.07 < 0.05 
Vitality 54.38 ± 23.76 45.42 ± 23.18 < 0.05 
 
Minimum N 
68 (NHP)  
72 (SF-36) 
77 (NHP) 
80 (SF-36) 
 
Subscale scores range: 0-100, higher score indicating better health status on SF-36, but 
poorer health status on NHP. 
Values are means ± SD. 
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Table 4: Characteristics of participants in the GH-withdrawal study  
 Placebo-
treated  
(N = 12) 
GH-treated 
(N = 9) 
P 
Men 6 4  
Women 6 5  
Mean age at baseline (years) 
[range] 
45.8 
[25 – 68]
43.8 
[25 - 66]
 
Mean duration of GH treatment 
(months) [range] 
61 
[12 - 132]
60 
[18 - 132] 
 
COGHD : AOGHD ratio 2 : 10 4 : 5  
BMI  at baseline (kg/ m2) 31.3 ± 8.3 24.7 ± 2.9 < 0.05 
Isolated GHD 0 2  
Gonadal hormone deficiency  8 6  
Thyroid hormone deficiency 9 5  
Corticosteroid deficiency 10 5  
Antidiuretic hormone deficiency 1 1  
Acromegaly 0 1  
Cushing’s disease 4 1  
Craniopharyngioma 1 1  
Chromophobe adenoma 4 1  
Macroprolactinoma 1 1  
Prolactinoma 1 1  
Traumatic hypopituitarism 1 0  
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Table 5: GH-treatment group means over the GH-withdrawal period  
Placebo-treated GH-treated  
Baseline Endpoint   Baseline Endpoint  
P  
NHP       
Emotional Reactions 13.86 ± 24.46  14.42 ± 24.91 3.78 ± 7.43  0.0 ± 0.0   
Energy 24.95 ± 35.06  26.33 ± 37.89 7.90 ± 15.18 7.9 ± 15.18  
Pain 4.12 ± 10.85  5.17 ± 17.14 4.77 ± 9.44 5.29 ± 12.77  
Physical Mobility 5.42 ± 15.74  7.15 ± 23.73 2.75 ± 7.77 5.42 ± 11.60  
Sleep 17.43 ± 25.98 21.67 ± 29.84 5.16 ± 7.20 0.0 ± 0.0  
Social Isolation 13.13 ± 24.11 13.09 ± 26.10 9.68 ± 14.08 0.0 ± 0.0  
SF-36       
Bodily Pain 72.08 ± 20.57 71.55 ± 28.00 70.0 ± 14.05 81.50 ± 27.52  
General Health 63.50 ± 19.58 57.00 ± 23.19 62.75 ± 23.89 66.12 ± 25.16 *p = 0.013 
Mental Health 75.00 ± 15.92 69.45 ± 21.04 77.5 ± 20.05 84.5 ± 7.23 *p = 0.027
Physical Functioning 78.52 ± 26.43 72.27 ±  30.20 83.13 ± 14.13 85.63 ± 15.45  
Role-Emotional 77.78 ± 35.77 63.33 ± 48.30 87.50 ± 35.36 91.67 ± 23.57  
Role-Physical 70.83 ± 39.65 72.73 ± 41.01 84.38 ± 18.60 90.63 ± 12.94  
Social Functioning 82.95 ± 25.78 77.27 ± 28.95 93.75 ± 9.45 90.63 ± 12.94  
Vitality 60.00 ± 22.76 51.82 ± 28.40 59.38 ± 15.22 60.0 ± 13.63  
 
Minimum N 
11 (NHP) 
11 (SF-36) 
11 (NHP) 
10 (SF-36) 
8 (NHP) 
8 (SF-36) 
6 (NHP) 
8(SF-36) 
 
*2-tailed.  Values are means ± SD. 
Subscale scores range: 0-100, higher score indicating better health status on SF-36, but poorer health status on NHP. 
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